37
Participants
Start Date
February 23, 2023
Primary Completion Date
March 1, 2026
Study Completion Date
March 1, 2026
ARV-471
Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until the recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
Abemaciclib
Daily oral dosages of Abemaciclib continuously, cycles lasting 28 days
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia, Candiolo
Clinica Universidad de Navarra, Madrid
Clínica Universidad de Navarra, Madrid
Hospital Universitario 12 de Octubre, Madrid
Clinica Universidad de Navarra, Pamplona
Moffitt Cancer Center - International Plaza, Tampa
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa
Moffitt McKinley Hospital, Tampa
Hospital Universitario Virgen Del Rocio, Seville
Siteman Cancer Center - WUPI, Shiloh
Siteman Cancer Center - North County, Florissant
Barnes-Jewish Hospital, St Louis
Washington University School of Medicine - Siteman Cancer Center, St Louis
Washington University School of Medicine, St Louis
Siteman Cancer Center - South County, St Louis
Siteman Cancer Center - West County, Creve Coeur
Siteman Cancer Center - St Peters, City of Saint Peters
U.T. MD Anderson Cancer Center, Investigational Pharmacy Services - Unit 376, Houston
U.T. MD Anderson Cancer Center, Houston
University of Texas MD Anderson Cancer Center, Houston
UCSF Medical Center at Mission Bay, San Francisco
Stanford Women's Cancer Center, Palo Alto
Northwest Medical Specialties, PLLC, Federal Way
Northwest Medical Specialties, PLLC, Gig Harbor
Northwest Medical Specialties, PLLC, Puyallup
Northwest Medical Specialties, PLLC, Bonney Lake
Northwest Medical Specialties, PLLC, Tacoma
BC Cancer Vancouver, Vancouver
BC Cancer Vancouver, Vancouver
The Ottawa Hospital - General Campus, Ottawa
Sunnybrook Research Institute, Toronto
CIUSSS- saguenay-Lac-Saint-Jean, Chicoutimi
Jewish General Hospital, Montreal
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Universitari Dexeus, Barcelona
Lead Sponsor
Arvinas Estrogen Receptor, Inc.
INDUSTRY
Pfizer
INDUSTRY